Hookipa Pharma Inc (HOOK) - Total Liabilities
Based on the latest financial reports, Hookipa Pharma Inc (HOOK) has total liabilities worth $24.02 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Hookipa Pharma Inc to track the company's year-over-year net asset growth rate.
Hookipa Pharma Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Hookipa Pharma Inc's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Hookipa Pharma Inc to measure how efficiently the company converts operating cash flow to free cash.
Hookipa Pharma Inc Competitors by Total Liabilities
The table below lists competitors of Hookipa Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TwentyFour Income Fund Ltd
LSE:TFIF
|
UK | GBX26.16 Million |
|
Biomaxima
WAR:BMX
|
Poland | zł30.50 Million |
|
Ecomiam SA
PA:ALECO
|
France | €7.48 Million |
|
TAO Synergies Inc.
NASDAQ:TAOX
|
USA | $1.69 Million |
|
TS Corp Preference Shares
KO:001795
|
Korea | ₩771.33 Billion |
|
Biovie Inc
NASDAQ:BIVI
|
USA | $1.91 Million |
|
Advanced Packaging Tech (Malaysia)
KLSE:9148
|
Malaysia | RM25.58 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Hookipa Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see HOOK market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hookipa Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hookipa Pharma Inc (2017–2025)
The table below shows the annual total liabilities of Hookipa Pharma Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $9.34 Million | -70.19% |
| 2024-12-31 | $31.33 Million | -56.17% |
| 2023-12-31 | $71.48 Million | +5.22% |
| 2022-12-31 | $67.94 Million | +86.37% |
| 2021-12-31 | $36.45 Million | +15.02% |
| 2020-12-31 | $31.69 Million | +22.63% |
| 2019-12-31 | $25.85 Million | +8.36% |
| 2018-12-31 | $23.85 Million | -79.51% |
| 2017-12-31 | $116.39 Million | -- |
About Hookipa Pharma Inc
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancer… Read more